Skip to main content

The Thyroid Risk
Decision Tree

The FDA requires a black box warning on all GLP-1 medications regarding thyroid tumors. This clinical framework translates that warning into a factual assessment of your personal risk profile.

✉️ Email Assessment
The Clinical Anchor
FDA: Semaglutide Safety Information →

The Risk Assessment Framework

The Fact Check: The thyroid tumors observed in clinical trials occurred in rodents, which have high amounts of GLP-1 receptors in their thyroid glands. Humans have extremely low levels of these specific receptors in the thyroid. The human risk is highly specific and largely genetic.

Phase 1: Personal Genetic History
  • Question: Do you or a first-degree relative (parent, sibling, child) have a history of Medullary Thyroid Carcinoma (MTC)?
  • Question: Do you have a personal or family diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)?
  • The Outcome: If you answered YES to either question, GLP-1 therapies are clinically contraindicated. You must consult an endocrinologist for alternative metabolic interventions. If you answered NO, proceed to Phase 2.
Phase 2: Common Thyroid Conditions
  • Question: Do you have Hypothyroidism (Hashimoto's) or Hyperthyroidism (Graves' disease)?
  • The Outcome: These common conditions are NOT contraindications for GLP-1 use. MTC is a highly specific, rare cancer of the C-cells, unrelated to general autoimmune thyroid dysfunction. You are generally cleared to proceed with provider supervision.
Phase 3: Active Monitoring
  • The Baseline: Before starting therapy, have your provider palpate your neck for active nodules.
  • The Symptoms to Watch: Once on therapy, report any new, persistent hoarseness, difficulty swallowing, shortness of breath, or a visible mass in the neck to your provider immediately.